BONIVA Patient Education Materials

We want to provide you with helpful information about BONIVA that you can share with your patients. That’s why we’ve made the following materials available to you.

Please download a copy of our educational brochure in your patient's preferred language.

English (Adobe^® Acrobat^® file)
Spanish (Adobe^® Acrobat^® file)
Chinese (Adobe^® Acrobat^® file)
Russian (Adobe^® Acrobat^® file)
Korean (Adobe^® Acrobat^® file)
Vietnamese (Adobe^® Acrobat^® file)

Please download a copy of our helpful BONIVA Fact Sheet in your patient’s preferred language:

*Requires Adobe^® Acrobat^® Reader^®. Visit Adobe^® Acrobat^® Reader^® to install.

BONIVA is indicated for the management of postmenopausal osteoporosis.

Important Safety Information for BONIVA Tablets
BONIVA Tablets are contraindicated in patients with known hypersensitivity to any component of this product, with hypocalcemia, or the inability to stand or sit upright for at least 60 minutes. Hypocalcemia and other disturbances of bone and mineral metabolism should be treated before starting therapy. Adequate intake of calcium and vitamin D is important in all patients.

BONIVA, like other bisphosphonates administered orally, may cause upper gastrointestinal (GI) disorders such as dysphagia, esophagitis, and esophageal or gastric ulcers. Discontinue use if new or worsening symptoms occur. As aspirin, NSAIDs, and bisphosphonates are associated with GI irritation, caution should be exercised when using them concomitantly. BONIVA Tablets should be taken at least 60 minutes before any oral medication or supplementation including calcium, antacids, or vitamins. Patients have reported severe bone, joint, and/or muscle pain after taking BONIVA and other bisphosphonate therapy for osteoporosis. Consider discontinuation of use if severe symptoms develop. Osteonecrosis of the jaw has been reported in patients treated with bisphosphonates; most cases have been in cancer patients undergoing dental procedures. BONIVA is not recommended for use in patients with severe renal impairment (creatinine clearance <30 mL/min). The overall adverse event profile of BONIVA 2.5 mg once daily was similar to that of placebo. In a one-year study comparing BONIVA 150 mg once-monthly and BONIVA 2.5 mg daily in patients with postmenopausal osteoporosis, the most commonly reported adverse events (>5%), regardless of causality, were abdominal pain (BONIVA 150 mg 7.8% vs BONIVA 2.5 mg 5.3%), hypertension (6.3% vs 7.3%), dyspepsia (5.6% vs 7.1%), arthralgia (5.6% vs 3.5%), nausea (5.1% vs 4.8%), and diarrhea (5.1% vs 4.1%). In a study of postmenopausal women with osteopenia the overall pattern of adverse events for BONIVA 150 mg once monthly was similar to that previously observed.

This site is intended for U.S. residents only.

The information provided on this site is for informational purposes only and does not take the place of talking to your healthcare provider about your medical condition or treatment.

Privacy Policy | Legal Statement | Contact Us | Unsubscribe

BONIVA and symbol are trademarks of Roche Therapeutics Inc.
MyBONIVA is a registered trademark of Roche Therapeutics Inc.